

Contralateral risk-reducing mastectomy in *BRCA1* and *BRCA2* mutation carriers and other high-risk women in the Kathleen Cuninghame Foundation Consortium for Research into Familial Breast Cancer (kConFab)

Belinda E. Kiely · Mark A. Jenkins · Joanne M. McKinley ·
Michael L. Friedlander · Prue Weideman · Roger L. Milne ·
Sue-Anne McLachlan · John L. Hopper · Kelly-Anne Phillips

Published online: 4 September 2009
© Springer Science+Business Media, LLC. 2009

Erratum to: Breast Cancer Res Treat
DOI 10.1007/s10549-009-0497-8

Unfortunately a wrong version of Fig. 1 has been given in the original publication of this article. The correct version is given below:

The online version of the original article can be found under doi:
[10.1007/s10549-009-0497-8](https://doi.org/10.1007/s10549-009-0497-8).

B. E. Kiely · J. M. McKinley · P. Weideman ·
K.-A. Phillips (✉)
Division of Haematology and Medical Oncology, Peter
MacCallum Cancer Centre, Locked Bag 1, A'Beckett St,
Melbourne, VIC 8006, Australia
e-mail: kelly.phillips@petermac.org

M. A. Jenkins · R. L. Milne · J. L. Hopper · K.-A. Phillips
Centre for Molecular, Environmental, Genetic & Analytic
Epidemiology, School of Population Health, The University
of Melbourne, Melbourne, VIC, Australia

M. L. Friedlander
Department of Medical Oncology, Prince of Wales Hospital,
Randwick, NSW, Australia

R. L. Milne
Genetic and Molecular Epidemiology Group, Human Cancer
Genetics Programme, Spanish National Cancer Research Centre
(CNIO), Madrid, Spain

S.-A. McLachlan
Department of Medical Oncology, St Vincent's Hospital,
Fitzroy, VIC, Australia

S.-A. McLachlan · K.-A. Phillips
Department of Medicine, The University of Melbourne,
Melbourne, VIC, Australia




Fig. 1 Schema for patients BC = breast cancer; CRRM = contralateral risk-reducing mastectomy; DCIS = ductal carcinoma in situ; f/up = follow-up; +ve = positive. ^a Includes seven women who learnt positive mutation result after CRRM